GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioventus Inc (NAS:BVS) » Definitions » Cash Flow from Investing

Bioventus (Bioventus) Cash Flow from Investing : $29.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bioventus Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Bioventus spent $0.3 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.7 Mil for other investing activities. In all, Bioventus spent $1.0 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Bioventus Cash Flow from Investing Historical Data

The historical data trend for Bioventus's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventus Cash Flow from Investing Chart

Bioventus Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only -7.91 -20.50 -283.76 -116.44 15.81

Bioventus Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.07 33.50 -2.04 -0.59 -1.00

Bioventus Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Bioventus's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Bioventus's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $29.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventus  (NAS:BVS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Bioventus's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.3 Mil. It means Bioventus spent $0.3 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Bioventus's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.0 Mil. It means Bioventus gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Bioventus's purchase of business for the three months ended in Mar. 2024 was $0.0 Mil. It means Bioventus spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Bioventus's sale of business for the three months ended in Mar. 2024 was $0.0 Mil. It means Bioventus gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Bioventus's purchase of investment for the three months ended in Mar. 2024 was $0.0 Mil. It means Bioventus spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Bioventus's sale of investment for the three months ended in Mar. 2024 was $0.0 Mil. It means Bioventus gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Bioventus's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.0 Mil. It means Bioventus paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Bioventus's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.0 Mil. It means Bioventus paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Bioventus's cash from other investing activities for the three months ended in Mar. 2024 was $-0.7 Mil. It means Bioventus paid $0.7 Mil for other investing activities.


Bioventus Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Bioventus's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventus (Bioventus) Business Description

Traded in Other Exchanges
N/A
Address
4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in U.S and International markets.
Executives
Bihl Anthony P Iii director, officer: Interim CEO 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
John A. Bartholdson director, 10 percent owner C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Juniper Investment Company, Llc 10 percent owner 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315
Katrina J Church officer: SVP & Chief Compliance Officer 3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303
Alexis P Michas 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Juniper Targeted Opportunities, Lp 10 percent owner 555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022
Juniper Targeted Opportunity Fund, L.p. 10 percent owner 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Mark Leonard Singleton officer: SEE REMARKS C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Anthony D'adamio officer: SVP & General Counsel C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Kenneth Michael Reali director, officer: Chief Executive Officer 5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613
John Nosenzo officer: Chief Commercial Officer C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Alessandra Pavesio officer: SVP & Chief Science Officer C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gregory O. Anglum officer: SVP and CFO C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703